Innovacell
Innovacell develops regenerative medicine products for treating fecal and urinary incontinence.
Innovacell (Ticker: 504A JP) develops regenerative medicine products specifically for treating fecal and urinary incontinence, while continuing research and development. Founded in 2021, the company is headquartered in Tokyo. Its key subsidiary, Innovacell GmbH, is located in Innsbruck, Austria. Representative Director Jason Seger leads the company.
The scheduled listing date on Tokyo Stock Exchange was February 24, 2026. The proposed offering comprises 9,130,000 shares at an indicative price range of JPY 1290–1350 per share. At the indicative range midpoint, the base offering would represent JPY 12.05 billion, approximately $76.28 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is approximately $280.00 million.
Nomura Securities is the lead underwriter, and SBI Securities is also participating.
Prepared with IPOX® AI assistance. Information may contain errors.
Prepared with IPOX® AI assistance. Information may contain errors.